Cargando…
PD11 - Omalizumab in children: experience in the Immunoallergology Department
Autores principales: | Aguiar, Rita, Silva, Pedro, Cabral Duarte, Fátima, Mendes, Ana, Célia Costa, Ana, Pereira, Manuel Barbosa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082038/ http://dx.doi.org/10.1186/2045-7022-4-S1-P11 |
Ejemplares similares
-
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
por: Aguiar, Rita, et al.
Publicado: (2014) -
Frequency of LTP (Pru p 3) and Profilin (Pru p 4) sensitisation in 1052 patients referenced to an immunoallergology department in Lisbon
por: Pereira Santos, M Conceição, et al.
Publicado: (2014) -
Efficacy and safety of omalizumab treatment to facilitate successful oral desensitisation in high-risk milk-allergic patients
por: Aguiar, Rita, et al.
Publicado: (2015) -
Type B adverse drug reactions reported by an immunoallergology department
por: Costa, Maria J., et al.
Publicado: (2018) -
PD49 - Induced sputum versus exhaled nitric oxide for the evaluation of airway inflammation in allergic pediatric asthma patients treated with omalizumab
por: Vilella, Mireia, et al.
Publicado: (2014)